ReviewMolecular neurobiology2026
Exosomal Cargoes Derived from Neural Stem Cell: A New Strategy of Parkinson's Disease Treatment.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the prevalent neurodegenerative diseases is Parkinson's disease (PD). It is characterized by progressive degeneration of the dopaminergic (DAergic) neurons in substantia nigra pars compacta (SNc). Unfortunately, no effective and definitive treatment solution has been provided for this disease. Therefore, the efforts of scientists to find more effective and efficient treatment methods for this disease continue. Technology based on neural stem cells (NSCs) is important in therapeutic goals for disorders such as PD. In addition to the proliferation and self-renewal, NSCs also can differentiate into neurons, astrocytes, oligodendrocytes, as well as DAergic neurons. The purpose of transplanted NSCs is to either stimulate and/or support the proliferation, survival, migration, and differentiation of endogenous NSCs or to restore lost cells. Exosome therapy is another important research area after NSCs therapy. Exosomes, a key element of the CNS microenvironment, mediate intercellular communication via transferring bioactive molecules. Exosomes produced by NSCs can play a significant role in the treatment of PD, by having neuroregulatory and repair functions. In addition, exosomes can readily penetrate the blood-brain barrier (BBB). In comparison with their parental stem cells, exosomes have antioxidant, anti-apoptotic, immunomodulatory properties, immune tolerance, and lower tumorigenic risk. Today, research in the field of the application of NSCs-derived exosomes as a novel approach to stimulate cell survival and enhance DAergic neurons' differentiation in PD is one of the greatest exciting subjects. But there is still a long way to go before using this strategy to treat PD in terms of safety and efficiency. Due to the potential effects of exosomes in the regulation of NSCs, in this review study, we focused on the underlying mechanism of NSCs and NSCs-derived exosomes and suggest a novel therapeutic target for PD. In general, NSCs represent a promising approach to treating neurological diseases such as PD.
Indexed as
Identifiers
41484489What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.